← All trials
NCT04720157
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 9, 2021
- Primary completion
- Aug 29, 2024
- Completion date
- Dec 18, 2025
- First posted
- Jan 22, 2021
- Last posted
- Dec 2, 2021
- Enrollment
- 1126
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- NovartisLead sponsor
- NovartisStudy director
- Alliance Foundation TrialsCollaborator
- RTOG FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.